Please input keywords

YH006 is a potentially first-in-class CTLA-4 x OX40 bispecific antibody for the treatment of solid tumors. YH006 simultaneously binds both CTLA-4 and OX40 to enhance the antineoplastic activity while at the same time decreasing the adverse effects of immunotherapy. It is currently at CMC stage.
naver-site-verification: naver8a6b0412e3d2d9dd38f1684b831435ac.html